Neuland Laboratories Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 17000 as of 12 May 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Neuland Laboratories Ltd for the Mar '26 is ₹ 788.71 crore as compare to the Dec '25 revenue of ₹ 447.76 crore. This represent the growth of 76.15% The revenue of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Neuland Laboratories Ltd for the Mar '26 is ₹ 319.79 crore as compare to the Dec '25 ebitda of ₹ 85.19 crore. This represent the growth of 275.38% The ebitda of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 212.67 crore over 8 quarters. This represents a CAGR of 47.41% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Neuland Laboratories Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or Parmax Pharma Ltd?

Market cap of Neuland Laboratories Ltd is 21,811 Cr while Market cap of Parmax Pharma Ltd is 12 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and Parmax Pharma Ltd?

The stock performance of Neuland Laboratories Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and Parmax Pharma Ltd?

As of May 12, 2026, the Neuland Laboratories Ltd stock price is INR ₹17000.55. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.1.

How do dividend payouts of Neuland Laboratories Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.